Symbols

CYRX

Cryoport·NASDAQ

--(--)

CYRX fundamentals

CYRX Q4 2025 Earnings

Cryoport (CYRX) released its earnings on Mar 3, 2026: revenue was 45.45M (YoY -23.65%), beat estimates; EPS was -0.27 (YoY +35.71%), missed estimates.

Revenue / YoY

45.45M

-23.65%

EPS / YoY

-0.27

+35.71%

Report date

Mar 3, 2026

CYRX Earnings Call Summary for Q4,2025

Commercial Growth Acceleration: 2025 commercial cell and gene therapy revenue surged 29% to $33.4 million, now 20% of total revenue.
Pipeline Strength: 86 Phase III trials position Cryoport for future approvals, with 9 expected in 2026.
Strategic Leverage: DHL partnership and AI adoption drive operational efficiency, targeting H2 2026 positive EBITDA.
Market Expansion: New MVE products (e.g., Fusion 800) open underserved markets, supporting 7% segment growth.

Earnings

EPS

Revenue

Revenue & Expenses

CYRX has released its 2025 Q4 earnings report, with revenue of 45.45M, reflecting a YoY change of 9.64%, and net profit of -11.64M, showing a YoY change of 37.66%. The Sankey diagram below clearly presents CYRX's revenue sources and cost distribution.

Key Indicators

Cryoport (CYRX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Cryoport (CYRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Cryoport (CYRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Cryoport (CYRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown